bioAffinity Technologies, Inc.
BIAF Nasdaq
SEC CIK 1712762
Follow bioAffinity Technologies
Weekly email: filings, results
Revenue, last quarter
$1.1M
−26% vs same quarter last year
Net income
−$5.3M
−4.5% vs same quarter last year
EPS, diluted
−$5.89
Operating cash flow
−$3.9M
−56.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $6.2M | −$14.9M |
| FY24 | $9.4M | −$9M |
| FY23 | $2.5M | −$7.9M |
| FY22 | $4.8K | −$8.2M |
| FY21 | - | −$6.3M |
| FY20 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −171.6% | −242% |
| FY24 | −95.6% | −96.6% |
| FY23 | −314.8% | −313.4% |
| FY22 | −83511.5% | −169771.2% |
| FY21 | - | - |
| FY20 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$9.4M |
| FY24 | −$7.3M |
| FY23 | −$6.1M |
| FY22 | −$4.3M |
| FY21 | - |
| FY20 | - |
- bioAffinity Technologies
- Healthcare median
Show the numbers
| Year | bioAffinity Technologies | Healthcare median |
|---|---|---|
| FY25 | −242% | −30.6% |
| FY24 | −96.6% | −47% |
| FY23 | −313.4% | −58% |
| FY22 | −169771.2% | −80.4% |
| FY21 | - | −71.9% |
| FY20 | - | −62.2% |